Guggenheim Rates Rezolute (RZLT) buy, $11 Price Target
Guggenheim maintains its buy rating on RZLT, setting a price target of $11, a 175% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Guggenheim rated Rezolute, Inc. ($RZLT) "buy" with a $11 price target on June 15, 2026.
Since the rating, $RZLT is up 18.9% after 1 week, up 9.5% after 1 month and down 17.3% to date (from the $4.33 close on Jun 15, 2026).
Key Points
- Guggenheim reiterated its buy rating on RZLT on June 15, 2026, with a price target of $11.
- Guggenheim's $11 price target implies 175% upside from Rezolute, Inc.'s ($RZLT) current $4 share price.
- RZLT shares recently traded at $4.00, reflecting ongoing interest from analysts.
- Insiders at RZLT have been active, with CFO Daron Evans buying 10,000 shares at $2.85 on March 30, 2026.
Get $RZLT trade alerts by text
We text you when insiders, Congress or big funds trade $RZLT. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Rezolute, Inc. alert may contain errors. Disclosures
On June 15, 2026, Guggenheim reiterated its buy rating on RZLT, setting a price target of $11. The analyst Debjit Chattopadhyay continues to see potential in the stock, which recently traded at $4.00.
Other Institutional Activity in RZLT
Several institutional investors have made moves in RZLT. Federated Hermes, Inc. reduced its holdings by 3,544,053 shares, leaving it with 12,990,659 shares valued at about $39.6 million. RA Capital Management, L.P. held steady with 9,180,000 shares worth approximately $28 million. BlackRock, Inc. trimmed its position by 454,703 shares, bringing its total to 6,313,503 shares valued at around $19.3 million. Opaleye Management Inc. slightly increased its stake by 12,844 shares, now holding 6,300,000 shares valued at about $19.2 million. Meanwhile, Balyasny Asset Management L.P. added 541,560 shares, raising its holdings to 5,048,421 shares worth about $15.4 million.
Insider Buying and Selling at Rezolute, Inc.
Insider activity at RZLT has been notable. On March 30, 2026, CFO Daron Evans purchased 10,000 shares at an average price of $2.85. Earlier in March, on the 2nd, CEO Nevan Elam sold 27,618 shares at $2.99, and Chief Medical Officer Brian Kenneth Roberts sold 11,439 shares at the same price. Roberts also bought 28,000 shares at $1.70 on December 16, 2025.
Analysts Set New Price Targets
Guggenheim maintained its buy rating on RZLT with an $11 price target on June 15, 2026. On June 3, 2026, Maxim Group also maintained a buy rating, setting a target of $14, while Citizens upgraded the stock to a buy with an $11 target. Wedbush and BTIG both maintained buy ratings with a $6 target on the same day. Earlier, on June 2, 2026, HC Wainwright & Co. reiterated a buy rating with a $5 target.
Bottom Line
Guggenheim's reiteration of a buy rating with an $11 target suggests confidence in RZLT's future prospects. The stock's recent trading price of $4 indicates room for growth according to analysts. Institutional and insider activities provide additional insights into the market's view of RZLT. As always, investors should consider these analyst ratings as part of a broader investment strategy.
$RZLT price target
Rezolute, Inc. daily closes and this analyst's $11 target. Not advice.
Source: Guggenheim's rating change on $RZLT (Jun 15, 2026). Written by software, not financial advice. How we make alerts